APO Research
Talk to an analyst

APO RESEARCH · REPORT

Multi-cancer Early Detection (MCED) Tests

Compare research editions
View pricing & licenses

Selected research

Industry Research

Multi-cancer Early Detection (MCED) Tests Industry Research Report 2026

15 April 2026141 pages

Choose your research edition.

Industry ResearchMulti-cancer Early Detection (MCED) Tests Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Multi-cancer Early Detection (MCED) Tests Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Multi-cancer Early Detection (MCED) Tests Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multi-cancer Early Detection (MCED) Tests Market Outlook and Growth Opportunities 2026$4,250 USDMarket Analysis & ForecastGlobal Multi-cancer Early Detection (MCED) Tests Market Analysis and Forecast 2026-2032239 pages · $4,950 USD

Market perspective

The global Multi-cancer Early Detection (MCED) Tests market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Multi-cancer Early Detection (MCED) Tests market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Multi-cancer Early Detection (MCED) Tests market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Multi-cancer Early Detection (MCED) Tests market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Multi-cancer Early Detection (MCED) Tests include Guardant Health, Exact Sciences, Freenome, Epiginomics AG, Bio-techne, ThriveEarlier Detection, GRAIL, Inc., CellMax life and Berry Genomics, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

Read the full market overview

This report quantifies the global Multi-cancer Early Detection (MCED) Tests market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Multi-cancer Early Detection (MCED) Tests.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Multi-cancer Early Detection (MCED) Tests Market by Company

Guardant Health

Exact Sciences

Freenome

Epiginomics AG

Bio-techne

ThriveEarlier Detection

GRAIL, Inc.

CellMax life

Berry Genomics

Singlera Genomics

Geneseeq

BGI Genomics

Burning Rock Biotech Limited

New Horizon Health Limited

Yeasen Bio

Hangzhou Aoru Biotech

Amoy Diagnostics Co., Ltd.

Genetron Health

AnchorDx

Surexam Bio-Tech Co.,Ltd.

HaploX

HefeiLaierBiotechnologyCo.,Ltd

Multi-cancer Early Detection (MCED) Tests Segment by Type

ctDNA Detection

CTC Detection

Exosome Detection

Multi-cancer Early Detection (MCED) Tests Segment by Application

Medical Institutions

Physical Examination Centers

Multi-cancer Early Detection (MCED) Tests Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Russia

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multi-cancer Early Detection (MCED) Tests market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multi-cancer Early Detection (MCED) Tests and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multi-cancer Early Detection (MCED) Tests.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6: Detailed analysis of Multi-cancer Early Detection (MCED) Tests companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Multi-cancer Early Detection (MCED) Tests Market Size by Type (2021-2026) & (US$ Million) Table 6. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2021-2026) Table 7. Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Type (2027-2032) & (US$ Million) Table 8. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Type (2027-2032) Table 9. Global Multi-cancer Early Detection (MCED) Tests Market Size by Application (2021-2026) & (US$ Million) Table 10. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2021-2026) Table 11. Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Application (2027-2032) & (US$ Million) Table 12. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Application (2027-2032) Table 13. Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Multi-cancer Early Detection (MCED) Tests Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region (2021-2026) Table 16. Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region (2027-2032) Table 18. Multi-cancer Early Detection (MCED) Tests Industry Trends Table 19. Multi-cancer Early Detection (MCED) Tests Industry Drivers Table 20. Multi-cancer Early Detection (MCED) Tests Industry Opportunities and Challenges Table 21. Multi-cancer Early Detection (MCED) Tests Market Restraints Table 22. Global Top Multi-cancer Early Detection (MCED) Tests Players by Revenue (US$ Million) & (2021-2026) Table 23. Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2021-2026) Table 24. Global Multi-cancer Early Detection (MCED) Tests Industry Players Ranking, 2024 VS 2025 VS 2026 Table 25. Global Key Players of Multi-cancer Early Detection (MCED) Tests, Headquarters and Area Served Table 26. Global Multi-cancer Early Detection (MCED) Tests Players, Product Type & Application Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Multi-cancer Early Detection (MCED) Tests by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Players Mergers & Acquisitions, Expansion Plans Table 30. North America Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 31. North America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026) & (US$ Million) Table 32. North America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032) & (US$ Million) Table 33. Europe Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Europe Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026) & (US$ Million) Table 35. Europe Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032) & (US$ Million) Table 36. Asia Pacific Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Asia Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Region (2021-2026) & (US$ Million) Table 38. Asia Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032) & (US$ Million) Table 39. South America Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 40. South America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026) & (US$ Million) Table 41. South America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032) & (US$ Million) Table 42. Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 43. Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026) & (US$ Million) Table 44. Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032) & (US$ Million) Table 45. Guardant Health Company Information Table 46. Guardant Health Business Overview Table 47. Guardant Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 48. Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 49. Guardant Health Recent Developments Table 50. Exact Sciences Company Information Table 51. Exact Sciences Business Overview Table 52. Exact Sciences Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 53. Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 54. Exact Sciences Recent Developments Table 55. Freenome Company Information Table 56. Freenome Business Overview Table 57. Freenome Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 58. Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 59. Freenome Recent Developments Table 60. Epiginomics AG Company Information Table 61. Epiginomics AG Business Overview Table 62. Epiginomics AG Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 63. Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 64. Epiginomics AG Recent Developments Table 65. Bio-techne Company Information Table 66. Bio-techne Business Overview Table 67. Bio-techne Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 68. Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 69. Bio-techne Recent Developments Table 70. ThriveEarlier Detection Company Information Table 71. ThriveEarlier Detection Business Overview Table 72. ThriveEarlier Detection Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 73. ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 74. ThriveEarlier Detection Recent Developments Table 75. GRAIL, Inc. Company Information Table 76. GRAIL, Inc. Business Overview Table 77. GRAIL, Inc. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 78. GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 79. GRAIL, Inc. Recent Developments Table 80. CellMax life Company Information Table 81. CellMax life Business Overview Table 82. CellMax life Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 83. CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 84. CellMax life Recent Developments Table 85. Berry Genomics Company Information Table 86. Berry Genomics Business Overview Table 87. Berry Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 88. Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 89. Berry Genomics Recent Developments Table 90. Singlera Genomics Company Information Table 91. Singlera Genomics Business Overview Table 92. Singlera Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 93. Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 94. Singlera Genomics Recent Developments Table 95. Geneseeq Company Information Table 96. Geneseeq Business Overview Table 97. Geneseeq Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 98. Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 99. Geneseeq Recent Developments Table 100. BGI Genomics Company Information Table 101. BGI Genomics Business Overview Table 102. BGI Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 103. BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 104. BGI Genomics Recent Developments Table 105. Burning Rock Biotech Limited Company Information Table 106. Burning Rock Biotech Limited Business Overview Table 107. Burning Rock Biotech Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 108. Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 109. Burning Rock Biotech Limited Recent Developments Table 110. New Horizon Health Limited Company Information Table 111. New Horizon Health Limited Business Overview Table 112. New Horizon Health Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 113. New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 114. New Horizon Health Limited Recent Developments Table 115. Yeasen Bio Company Information Table 116. Yeasen Bio Business Overview Table 117. Yeasen Bio Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 118. Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 119. Yeasen Bio Recent Developments Table 120. Hangzhou Aoru Biotech Company Information Table 121. Hangzhou Aoru Biotech Business Overview Table 122. Hangzhou Aoru Biotech Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 123. Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 124. Hangzhou Aoru Biotech Recent Developments Table 125. Amoy Diagnostics Co., Ltd. Company Information Table 126. Amoy Diagnostics Co., Ltd. Business Overview Table 127. Amoy Diagnostics Co., Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 128. Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 129. Amoy Diagnostics Co., Ltd. Recent Developments Table 130. Genetron Health Company Information Table 131. Genetron Health Business Overview Table 132. Genetron Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 133. Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 134. Genetron Health Recent Developments Table 135. AnchorDx Company Information Table 136. AnchorDx Business Overview Table 137. AnchorDx Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 138. AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 139. AnchorDx Recent Developments Table 140. Surexam Bio-Tech Co.,Ltd. Company Information Table 141. Surexam Bio-Tech Co.,Ltd. Business Overview Table 142. Surexam Bio-Tech Co.,Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 143. Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 144. Surexam Bio-Tech Co.,Ltd. Recent Developments Table 145. HaploX Company Information Table 146. HaploX Business Overview Table 147. HaploX Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 148. HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 149. HaploX Recent Developments Table 150. HefeiLaierBiotechnologyCo.,Ltd Company Information Table 151. HefeiLaierBiotechnologyCo.,Ltd Business Overview Table 152. HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) & (US$ Million) Table 153. HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio Table 154. HefeiLaierBiotechnologyCo.,Ltd Recent Developments Table 155. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Multi-cancer Early Detection (MCED) Tests Product Image Figure 5. Global Multi-cancer Early Detection (MCED) Tests Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 6. Global Multi-cancer Early Detection (MCED) Tests Market Share by Type: 2025 VS 2032 Figure 7. ctDNA Detection Product Figure 8. CTC Detection Product Figure 9. Exosome Detection Product Figure 10. Global Multi-cancer Early Detection (MCED) Tests Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Multi-cancer Early Detection (MCED) Tests Market Share by Application: 2025 VS 2032 Figure 12. Medical Institutions Product Figure 13. Physical Examination Centers Product Figure 14. Global Multi-cancer Early Detection (MCED) Tests Market Size (US$ Million), Year-over-Year: 2021-2032 Figure 15. Global Multi-cancer Early Detection (MCED) Tests Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Multi-cancer Early Detection (MCED) Tests Market Share by Region: 2025 VS 2032 Figure 17. Global Multi-cancer Early Detection (MCED) Tests Market Share by Players in 2025 Figure 18. Global Multi-cancer Early Detection (MCED) Tests Manufacturers Established Date Figure 19. Global Top 5 and 10 Multi-cancer Early Detection (MCED) Tests Players Market Share by Revenue in 2025 Figure 20. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. North America Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 22. North America Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 23. United States Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 24. Canada Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 25. Mexico Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 26. Europe Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Europe Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 28. Germany Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. France Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 30. U.K. Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Italy Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 32. Spain Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Russia Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 34. Netherlands Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 35. Nordic Countries Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 37. Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 38. China Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 39. Japan Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 40. South Korea Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 41. India Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 42. India Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 43. Australia Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 44. China Taiwan Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 45. Southeast Asia Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 46. South America Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 47. South America Multi-cancer Early Detection (MCED) Tests Market Share by Country (2021-2032) Figure 48. Brazil Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 49. Argentina Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 50. Chile Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 51. Colombia Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 52. Peru Multi-cancer Early Detection (MCED) Tests Market Size YoY Growth (2021-2032) & (US$ Million) Figure 53. Guardant Health Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 54. Exact Sciences Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 55. Freenome Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 56. Epiginomics AG Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 57. Bio-techne Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 58. ThriveEarlier Detection Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 59. GRAIL, Inc. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 60. CellMax life Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 61. Berry Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 62. Singlera Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 63. Geneseeq Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 64. BGI Genomics Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 65. Burning Rock Biotech Limited Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 66. New Horizon Health Limited Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 67. Yeasen Bio Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 68. Hangzhou Aoru Biotech Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 69. Amoy Diagnostics Co., Ltd. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 70. Genetron Health Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 71. AnchorDx Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 72. Surexam Bio-Tech Co.,Ltd. Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 73. HaploX Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026) Figure 74. HefeiLaierBiotechnologyCo.,Ltd Revenue Growth Rate in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)

Scope & coverage.

Types
  • ctDNA Detection
  • CTC Detection
  • Exosome Detection
Applications
  • Medical Institutions
  • Physical Examination Centers
Companies covered
  • Guardant Health
  • Exact Sciences
  • Freenome
  • Epiginomics AG
  • Bio-techne
  • ThriveEarlier Detection
  • GRAIL, Inc.
  • CellMax life
  • Berry Genomics
  • Singlera Genomics
  • Geneseeq
  • BGI Genomics
  • Burning Rock Biotech Limited
  • New Horizon Health Limited
  • Yeasen Bio
  • Hangzhou Aoru Biotech
  • Amoy Diagnostics Co., Ltd.
  • Genetron Health
  • AnchorDx
  • Surexam Bio-Tech Co.,Ltd.
  • HaploX
  • HefeiLaierBiotechnologyCo.,Ltd

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Multi-cancer Early Detection (MCED) Tests by Type
  3. 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
  4. 2.2.2 ctDNA Detection
  5. 2.2.3 CTC Detection
  6. 2.2.4 Exosome Detection
  7. 2.3 Multi-cancer Early Detection (MCED) Tests by Application
  8. 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  9. 2.3.2 Medical Institutions
  10. 2.3.3 Physical Examination Centers
  11. 2.4 Assumptions and Limitations
3 Multi-cancer Early Detection (MCED) Tests Breakdown Data by Type
  1. 3.1 Global Multi-cancer Early Detection (MCED) Tests Historic Market Size by Type (2021-2026)
  2. 3.2 Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Type (2027-2032)
4 Multi-cancer Early Detection (MCED) Tests Breakdown Data by Application
  1. 4.1 Global Multi-cancer Early Detection (MCED) Tests Historic Market Size by Application (2021-2026)
  2. 4.2 Global Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
  1. 5.1 Global Multi-cancer Early Detection (MCED) Tests Market Perspective (2021-2032)
  2. 5.2 Global Multi-cancer Early Detection (MCED) Tests Growth Trends by Region
  3. 5.2.1 Global Multi-cancer Early Detection (MCED) Tests Market Size by Region: 2021 VS 2025 VS 2032
  4. 5.2.2 Multi-cancer Early Detection (MCED) Tests Historic Market Size by Region (2021-2026)
  5. 5.2.3 Multi-cancer Early Detection (MCED) Tests Forecasted Market Size by Region (2027-2032)
  6. 5.3 Multi-cancer Early Detection (MCED) Tests Market Dynamics
  7. 5.3.1 Multi-cancer Early Detection (MCED) Tests Industry Trends
  8. 5.3.2 Multi-cancer Early Detection (MCED) Tests Market Drivers
  9. 5.3.3 Multi-cancer Early Detection (MCED) Tests Market Challenges
  10. 5.3.4 Multi-cancer Early Detection (MCED) Tests Market Restraints
6 Market Competitive Landscape by Players
  1. 6.1 Global Top Multi-cancer Early Detection (MCED) Tests Players by Revenue
  2. 6.1.1 Global Top Multi-cancer Early Detection (MCED) Tests Players by Revenue (2021-2026)
  3. 6.1.2 Global Multi-cancer Early Detection (MCED) Tests Revenue Market Share by Players (2021-2026)
  4. 6.2 Global Multi-cancer Early Detection (MCED) Tests Industry Players Ranking, 2023 VS 2024 VS 2025
  5. 6.3 Global Key Players of Multi-cancer Early Detection (MCED) Tests Head Office and Area Served
  6. 6.4 Global Multi-cancer Early Detection (MCED) Tests Players, Product Type & Application
  7. 6.5 Global Multi-cancer Early Detection (MCED) Tests Manufacturers Established Date
  8. 6.6 Global Multi-cancer Early Detection (MCED) Tests Market CR5 and HHI
  9. 6.7 Global Players Mergers & Acquisition
7 North America
  1. 7.1 North America Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  2. 7.2 North America Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 7.3 North America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026)
  4. 7.4 North America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032)
  5. 7.5 United States
  6. 7.5 United States
  7. 7.6 Canada
  8. 7.7 Mexico
8 Europe
  1. 8.1 Europe Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  2. 8.2 Europe Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 8.3 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026)
  4. 8.4 Europe Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032)
  5. 8.5 Germany
  6. 8.6 France
  7. 8.7 U.K.
  8. 8.8 Italy
  9. 8.9 Spain
  10. 8.10 Russia
  11. 8.11 Netherlands
  12. 8.12 Nordic Countries
9 Asia-Pacific
  1. 9.1 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  2. 9.2 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 9.3 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026)
  4. 9.4 Asia-Pacific Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032)
  5. 9.5 China
  6. 9.6 Japan
  7. 9.7 South Korea
  8. 9.8 India
  9. 9.9 Australia
  10. 9.10 China Taiwan
  11. 9.11 Southeast Asia
10 South America
  1. 10.1 South America Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  2. 10.2 South America Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 10.3 South America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026)
  4. 10.4 South America Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032)
  5. 10.5 Brazil
  6. 10.6 Argentina
  7. 10.7 Chile
  8. 10.8 Colombia
  9. 10.9 Peru
11 Middle East & Africa
  1. 11.1 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Size (2021-2032)
  2. 11.2 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Growth Rate by Country: 2021 VS 2025 VS 2032
  3. 11.3 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Size by Country (2021-2026)
  4. 11.4 Middle East & Africa Multi-cancer Early Detection (MCED) Tests Market Size by Country (2027-2032)
  5. 11.5 Saudi Arabia
  6. 11.6 Israel
  7. 11.7 United Arab Emirates
  8. 11.8 Turkey
  9. 11.9 Iran
  10. 11.10 Egypt
12 Players Profiled
  1. 12.1 Guardant Health
  2. 12.1.1 Guardant Health Company Information
  3. 12.1.2 Guardant Health Business Overview
  4. 12.1.3 Guardant Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  5. 12.1.4 Guardant Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  6. 12.1.5 Guardant Health Recent Developments
  7. 12.2 Exact Sciences
  8. 12.2.1 Exact Sciences Company Information
  9. 12.2.2 Exact Sciences Business Overview
  10. 12.2.3 Exact Sciences Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  11. 12.2.4 Exact Sciences Multi-cancer Early Detection (MCED) Tests Product Portfolio
  12. 12.2.5 Exact Sciences Recent Developments
  13. 12.3 Freenome
  14. 12.3.1 Freenome Company Information
  15. 12.3.2 Freenome Business Overview
  16. 12.3.3 Freenome Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  17. 12.3.4 Freenome Multi-cancer Early Detection (MCED) Tests Product Portfolio
  18. 12.3.5 Freenome Recent Developments
  19. 12.4 Epiginomics AG
  20. 12.4.1 Epiginomics AG Company Information
  21. 12.4.2 Epiginomics AG Business Overview
  22. 12.4.3 Epiginomics AG Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  23. 12.4.4 Epiginomics AG Multi-cancer Early Detection (MCED) Tests Product Portfolio
  24. 12.4.5 Epiginomics AG Recent Developments
  25. 12.5 Bio-techne
  26. 12.5.1 Bio-techne Company Information
  27. 12.5.2 Bio-techne Business Overview
  28. 12.5.3 Bio-techne Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  29. 12.5.4 Bio-techne Multi-cancer Early Detection (MCED) Tests Product Portfolio
  30. 12.5.5 Bio-techne Recent Developments
  31. 12.6 ThriveEarlier Detection
  32. 12.6.1 ThriveEarlier Detection Company Information
  33. 12.6.2 ThriveEarlier Detection Business Overview
  34. 12.6.3 ThriveEarlier Detection Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  35. 12.6.4 ThriveEarlier Detection Multi-cancer Early Detection (MCED) Tests Product Portfolio
  36. 12.6.5 ThriveEarlier Detection Recent Developments
  37. 12.7 GRAIL, Inc.
  38. 12.7.1 GRAIL, Inc. Company Information
  39. 12.7.2 GRAIL, Inc. Business Overview
  40. 12.7.3 GRAIL, Inc. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  41. 12.7.4 GRAIL, Inc. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  42. 12.7.5 GRAIL, Inc. Recent Developments
  43. 12.8 CellMax life
  44. 12.8.1 CellMax life Company Information
  45. 12.8.2 CellMax life Business Overview
  46. 12.8.3 CellMax life Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  47. 12.8.4 CellMax life Multi-cancer Early Detection (MCED) Tests Product Portfolio
  48. 12.8.5 CellMax life Recent Developments
  49. 12.9 Berry Genomics
  50. 12.9.1 Berry Genomics Company Information
  51. 12.9.2 Berry Genomics Business Overview
  52. 12.9.3 Berry Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  53. 12.9.4 Berry Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  54. 12.9.5 Berry Genomics Recent Developments
  55. 12.10 Singlera Genomics
  56. 12.10.1 Singlera Genomics Company Information
  57. 12.10.2 Singlera Genomics Business Overview
  58. 12.10.3 Singlera Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  59. 12.10.4 Singlera Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  60. 12.10.5 Singlera Genomics Recent Developments
  61. 12.11 Geneseeq
  62. 12.11.1 Geneseeq Company Information
  63. 12.11.2 Geneseeq Business Overview
  64. 12.11.3 Geneseeq Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  65. 12.11.4 Geneseeq Multi-cancer Early Detection (MCED) Tests Product Portfolio
  66. 12.11.5 Geneseeq Recent Developments
  67. 12.12 BGI Genomics
  68. 12.12.1 BGI Genomics Company Information
  69. 12.12.2 BGI Genomics Business Overview
  70. 12.12.3 BGI Genomics Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  71. 12.12.4 BGI Genomics Multi-cancer Early Detection (MCED) Tests Product Portfolio
  72. 12.12.5 BGI Genomics Recent Developments
  73. 12.13 Burning Rock Biotech Limited
  74. 12.13.1 Burning Rock Biotech Limited Company Information
  75. 12.13.2 Burning Rock Biotech Limited Business Overview
  76. 12.13.3 Burning Rock Biotech Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  77. 12.13.4 Burning Rock Biotech Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  78. 12.13.5 Burning Rock Biotech Limited Recent Developments
  79. 12.14 New Horizon Health Limited
  80. 12.14.1 New Horizon Health Limited Company Information
  81. 12.14.2 New Horizon Health Limited Business Overview
  82. 12.14.3 New Horizon Health Limited Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  83. 12.14.4 New Horizon Health Limited Multi-cancer Early Detection (MCED) Tests Product Portfolio
  84. 12.14.5 New Horizon Health Limited Recent Developments
  85. 12.15 Yeasen Bio
  86. 12.15.1 Yeasen Bio Company Information
  87. 12.15.2 Yeasen Bio Business Overview
  88. 12.15.3 Yeasen Bio Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  89. 12.15.4 Yeasen Bio Multi-cancer Early Detection (MCED) Tests Product Portfolio
  90. 12.15.5 Yeasen Bio Recent Developments
  91. 12.16 Hangzhou Aoru Biotech
  92. 12.16.1 Hangzhou Aoru Biotech Company Information
  93. 12.16.2 Hangzhou Aoru Biotech Business Overview
  94. 12.16.3 Hangzhou Aoru Biotech Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  95. 12.16.4 Hangzhou Aoru Biotech Multi-cancer Early Detection (MCED) Tests Product Portfolio
  96. 12.16.5 Hangzhou Aoru Biotech Recent Developments
  97. 12.17 Amoy Diagnostics Co., Ltd.
  98. 12.17.1 Amoy Diagnostics Co., Ltd. Company Information
  99. 12.17.2 Amoy Diagnostics Co., Ltd. Business Overview
  100. 12.17.3 Amoy Diagnostics Co., Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  101. 12.17.4 Amoy Diagnostics Co., Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  102. 12.17.5 Amoy Diagnostics Co., Ltd. Recent Developments
  103. 12.18 Genetron Health
  104. 12.18.1 Genetron Health Company Information
  105. 12.18.2 Genetron Health Business Overview
  106. 12.18.3 Genetron Health Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  107. 12.18.4 Genetron Health Multi-cancer Early Detection (MCED) Tests Product Portfolio
  108. 12.18.5 Genetron Health Recent Developments
  109. 12.19 AnchorDx
  110. 12.19.1 AnchorDx Company Information
  111. 12.19.2 AnchorDx Business Overview
  112. 12.19.3 AnchorDx Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  113. 12.19.4 AnchorDx Multi-cancer Early Detection (MCED) Tests Product Portfolio
  114. 12.19.5 AnchorDx Recent Developments
  115. 12.20 Surexam Bio-Tech Co.,Ltd.
  116. 12.20.1 Surexam Bio-Tech Co.,Ltd. Company Information
  117. 12.20.2 Surexam Bio-Tech Co.,Ltd. Business Overview
  118. 12.20.3 Surexam Bio-Tech Co.,Ltd. Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  119. 12.20.4 Surexam Bio-Tech Co.,Ltd. Multi-cancer Early Detection (MCED) Tests Product Portfolio
  120. 12.20.5 Surexam Bio-Tech Co.,Ltd. Recent Developments
  121. 12.21 HaploX
  122. 12.21.1 HaploX Company Information
  123. 12.21.2 HaploX Business Overview
  124. 12.21.3 HaploX Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  125. 12.21.4 HaploX Multi-cancer Early Detection (MCED) Tests Product Portfolio
  126. 12.21.5 HaploX Recent Developments
  127. 12.22 HefeiLaierBiotechnologyCo.,Ltd
  128. 12.22.1 HefeiLaierBiotechnologyCo.,Ltd Company Information
  129. 12.22.2 HefeiLaierBiotechnologyCo.,Ltd Business Overview
  130. 12.22.3 HefeiLaierBiotechnologyCo.,Ltd Revenue in Multi-cancer Early Detection (MCED) Tests Business (2021-2026)
  131. 12.22.4 HefeiLaierBiotechnologyCo.,Ltd Multi-cancer Early Detection (MCED) Tests Product Portfolio
  132. 12.22.5 HefeiLaierBiotechnologyCo.,Ltd Recent Developments
13 Report Conclusion
    14 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst